Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.

NCT04469127 is registered in ClinicalTrials.gov with Advanced Imaging Projects, LLC as lead sponsor.

NCT NCT04469127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04469127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.
Lead sponsor
Advanced Imaging Projects, LLC
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2024
Completion date
August 30, 2025
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv